X4 Pharmaceuticals股价下跌5%，股价为1.35亿美元

• X4 Pharmaceuticals (NASDAQ:XFOR) priced its previously announced underwritten public offering of 45.86M shares at $2.90 and warrants to purchase up to 700K shares at a public offering price of $2.899 per pre-funded warrant.
• The aggregate gross proceeds to X4 are expected to be ~$135M.
• The offering is expected to close on October 27, 2025.
• The underwriters have an option for a period of 30 days to purchase up to an additional ~6.98M shares.
• Net proceeds, together with its existing cash and cash equivalents and cash flows from operations, will be used to fund the pivotal Phase 3 development of mavorixafor in certain chronic neutropenic disorders, as well as for general and administrative expenses, capital expenditures, working capital and other general corporate purposes.
• The stock price dropped 5.2% on Thursday during after-market hours of trading.

More on X4 Pharmaceuticals

• X4 Pharmaceuticals announces proposed underwritten public offering
• X4 Pharmaceuticals to reduce 50% of workforce
• Seeking Alpha’s Quant Rating on X4 Pharmaceuticals
• Historical earnings data for X4 Pharmaceuticals
• Financial information for X4 Pharmaceuticals